Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L.
Livraghi L, et al. Among authors: moretti e.
Eur J Cancer. 2024 Dec;213:115108. doi: 10.1016/j.ejca.2024.115108. Epub 2024 Oct 31.
Eur J Cancer. 2024.
PMID: 39522332
Free article.